

FULL VALUE OF VACCINE ASSESSMENT

GROUP B STREPTOCOCCUS VACCINE

FINANCIAL ANALYSIS



**World Health
Organization**

FULL VALUE OF VACCINE ASSESSMENT

GROUP B STREPTOCOCCUS VACCINE

FINANCIAL ANALYSIS



**World Health
Organization**

Group B streptococcus vaccine: full value of vaccine assessment. Financial analysis

ISBN 978 92 4 002551 6 (electronic version)

ISBN 978 92 4 002552 3 (print version)

© World Health Organization 2021

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (<http://www.wipo.int/amc/en/mediation/rules/>).

Suggested citation. Group B streptococcus vaccine: full value of vaccine assessment. Financial analysis. Geneva: World Health Organization; 2021. Licence: [CC BY-NC-SA 3.0 IGO](https://creativecommons.org/licenses/by-nc-sa/3.0/igo).

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <https://www.who.int/about/policies/publishing/copyright>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Cover photo credit: Louis Leeson/LSHTM2017

CONTENTS

Acknowledgements.....	iv
Executive summary.....	v
1. INTRODUCTION	1
2. OBJECTIVES	2
3. METHODS	3
Profit and loss statement.....	3
NPV Calculation.....	4
4. ASSUMPTIONS	5
Vaccine demand.....	5
Vaccine prices.....	6
Timeframe	7
Clinical development and manufacturing investments.....	7
Other market and financial assumptions	8
5. RESULTS	9
6. CONCLUSIONS	10
References.....	11

Acknowledgements

This report was developed by Stefano Malvolti and Melissa Malhame, MMGH Consulting and Philipp Lambach, WHO with review and inputs of a Technical Working Group and the project's overall Scientific Advisory Group.

Technical Working Group: Flor Munoz, Martina Baye, Lumbwe Chola, Michelle Giles, Asma Khalil, Elisabeth Mason, Sonja Merten, Baoping Yang.

Scientific Advisory Group: Liz Mason, Martina Lukong Baye, Lumbwe Chola, Paul T. Heath, Margaret Ip, Nicholas Kassebaum, Asma Khalil, Kirsty Le Doare, Shabir A. Madhi, Flor Munoz, Maarten Postma, Samir Saha, Stephanie Schrag, Stephane Verguet. Baoping Yang was consulted as representative of the WHO Immunization Practices Advisory Committee (IPAC).

Consultants/observers: Thomas Cherian, Jessica Fleming, Will Hausdorff, Carsten Mantel, Clint Pecenka, Caroline Trotter.

Additional experts: Tanja Cernuschi, Theresa Diaz, Martin Friede, Will Gardner, Birgitte Giersing, Bronner Goncalves, Tracey Goodman, Raymond Hutubessy, Mark Jit, Joy Lawn, Laura Nic Lochlainn, Allisyn Moran, Proma Paul, Marc Perut, Simon Procter, Messeret Shibeshi, Johan Vekemans.

Financial support for the development and pilot-testing of this report is provided through the Bill and Melinda Gates Foundation, which provides financial support to the World Health Organization Immunization, Vaccines and Biologicals department (INV-1175247).

Executive summary

As part of the development of a value assessment for a group B streptococcal (GBS) vaccine, an assessment was conducted on the return on investment and financial sustainability for vaccine manufacturers of developing and commercializing a GBS vaccine.

The assessment indicated that the development of a GBS vaccine could be finalized by 2028 with a total cost of some US\$ 226–378 million for completion of the clinical development and building a dedicated manufacturing plant. After achieving the first registration and WHO prequalification the vaccine could be rolled out globally as of 2029 based on countries' burden of disease, strength of immunization programme and maternal immunization platform.

Subject to different assumptions on vaccination schedules and target populations, the number of introducing countries and the strength of competition, the vaccine could generate up to US\$ 8 billion in sales over the period 2029–2040. This turnover could increase to US\$ 16 billion with a two-dose schedule with priming in adolescence and boosting during pregnancy or could be lowered to US\$ 1.9 billion if two competitors are in the market.

As a result, the net present value (NPV) of the initiative is US\$ 742 million in the base case, providing vaccine manufacturers with a significant return on the initial investment and hence making the vaccine development enterprise financially viable. The NPV can range up to US\$ 1.6 billion for two-dose scenarios. Importantly, the NPV remains positive under the most aggressive competition or most conservative clinical development scenarios. Of all pessimistic scenarios (lack of Gavi support, higher COGS, stronger competition, need for full efficacy trial) the NPV turns marginally negative (US\$ -34 million) only under the most conservative clinical development scenario (i.e. the need for a full efficacy trial). The results of these more pessimistic scenarios are evidence of an acceptable level of risk of the initiative that can absorb most unexpected deterioration of the assumptions of the base case.

On the basis of the simulated plan and market forces, the business case for the development of a GBS vaccine can be considered financially sustainable. It is likely to guarantee a sizeable return on investment without the need for any incentive beyond the market. These results should encourage manufacturers to focus their efforts on the development of a GBS vaccine that can have not only a solid public health value assessment but also a commercial one. Nonetheless, the role of donors or financiers can still prove very important in de-risking the development of the GBS vaccine that, especially at this stage, is still affected by many levels of uncertainty.

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_23529

